Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page
- CheckyesterdayChange DetectedThe page’s UI/backend revision label was updated from version v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a new MeSH term 'Primary interstitial lung disease specific to childhood' and a Genetic and Rare Diseases Information Center resources link to the study page.SummaryDifference0.1%

- Check37 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.4.3 replaces the previous v3.4.2 on the page.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.